Drugs previously used against Covid are now off-protocol

Significant changes have taken place in the medical management of Covid -19, the use of drugs that were previously part of the standard management of patients with the disease are currently excluded from the protocol.

Currently, given the high circulation of the omicron variant, whose symptoms are less aggressive, Dr. José Yunen, specialist in critical medicine and outpatient management of patients with Covid-19, recommends a treatment regimen based on four pillars, such as an antiviral, an antihistamine, a blood thinner, and a cough medicine.

He explains that right now in his treatment regimen for the patient who has symptoms of Covid-19, there is an antiviral, like favipiravir, which works very well applied at a lower dose than in previous variants and l use of antihistamines such as famotidine as studies indicate that high doses may decrease viral load.

He adds that since there are still no studies or clear information that establishes whether the omicron variant tends to create thrombi or clots, it is also recommended that coagulation therapy be applied to the patient, such as aspirin or the like in case of allergy patients, as well as a medicine to treat cough.

He misunderstands that patients vaccinated with Covid-19, believed to be the omicron variant, are applied to expensive monoclonal drugs.

According to him, two fundamental axes must be taken into account when treating the patient with Covid-19, the first being to determine how many vaccines he has applied, which ones, and when was his last dose because it is proven that six months that’s until a bit late for a booster dose of the vaccine regardless of the platform applied.

Hydroxychloroquine and ivermectin
Yunen recalls that several drugs have been used during the pandemic, some redirected, and others focused on Sars-CoV-2.

He cites hydroxychloroquine and ivermectin as two drugs that were initially widely used but have already been discontinued, leaving the treatment regimen for patients with Covid-19.

This week, he added, the US Food and Drug Administration (FDA) removed two monoclonal antibody therapies from the list of approved treatments for the disease.

He explained that these two drugs, which the FDA says are not effective against the omicron variant, are bamlanivimab and etesevimab – which are given together, from pharmaceutical company Eli Lilly – and Regeneron or REGEN-COV. composed of casirivimab and imdevimab, and only recommends the one from the pharmaceutical company Merk, which is Sotrovimab.

He added that antivirals such as intravenous remdesivir and empirically favipiravir continue to be used and that tocilizumab, which has been the savior since the start of the pandemic, continues to be the most potent inhibitor, being a marker that predicts cytokine storm.

There are two approved drugs, he added, that are still in use, such as Paxlovid, which is a mixture of two protease inhibitors, and Molnupiravir, which stops the virus from continuing to replicate.


In the middle of last year, the most used drugs were Remdesivir and Tocilizumab, Dexamethasone, blood thinners, convalescent plasma, and monoclonal antibodies and population.

Since the pandemic of 2020, the population has assumed the consumption of vitamins such as C, D and minerals such as zinc, among others, as part of their daily routine.

About Michael Bill

Check Also

Pfizer launches patient assistance app to improve affordability and access to medicines

Launch of IUdo app helps patients on support programs by providing greater accessibility to Pfizer …